India, Nov. 1 -- For millions of Indian families, a cancer diagnosis carries a dual terror: the physical devastation of the disease and the inevitable financial ruin that follows. For years, patients have navigated a pharmaceutical market where life-saving therapies were priced like luxury commodities, forcing households into debt, asset liquidation, and agonising choices between treatment cycles and basic survival. Now, a sweeping regulatory crackdown has pulled back the curtain on how deep those profit margins truly went.

Data released by the National Pharmaceutical Pricing Authority (NPPA), spanning comprehensive manufacturer filings up to 28 October 2026, reveals staggering price reductions of 50% to over 85% on critical non-schedule...